At the molecular level, the abrogation of CD133hi self-renewal with combined HT and tocilizumab led to ER protein re-expression in several models of experimental HT-resistant breast cancer occurring in a Stat3-dependent manner (Fig. 3h-full blots in Supplementary Fig. 8). The gene discussed is ESR1; the disease is breast carcinoma.